First Command Advisory Services, Inc. Clovis Oncology, Inc. Transaction History

First Command Advisory Services, Inc.

  • $10.4 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 21, 2022
SELL
$0.63 - $2.96 $3 - $17
-6 Closed
0 $0
Q1 2022

Apr 14, 2022
BUY
$1.43 - $3.14 $8 - $18
6 New
6 $0

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track First Command Advisory Services, Inc. Portfolio

Follow First Command Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Command Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Command Advisory Services, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email